Isa-KRd Produces Deep, Durable Response Rates in Newly Diagn

The addition of isatuximab-irfc to carfilzomib, lenalidomide, and dexamethasone was well tolerated and elicited a 100% objective response rate in standard- and high-risk, transplant-eligible patients with newly diagnosed multiple myeloma.

Related Keywords

, Elizabethk Odonnell , Dana Farber Cancer Institute , Drug Administration , Professor Of Medicine At Harvard Medical School , Early Detection , Assistant Professor , Harvard Medical School , Ash Annual Meeting , Phase 2 Skylark Trial Nct04430894 , Newly Diagnosed Multiple Myeloma Ndmm , Isatuximab Irfc , Carfilzomib , Lenalidomide ,